Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: Illustration for the Netherlands

PharmacoEconomics

Volumn 25, Issue 6, 2007, Pages 497-509

  Postma, Maarten J ^a   Novak, Annoesjka ^b   Scheijbeler, Huib W K F H ^a,c   Gyldmark, Marlene ^d   Van Genugten, Marianne L L ^e   Wilschut, Jan C ^f  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Roche Netherlands BV   (Netherlands)

^c IQVIA   (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e MAPI GROUP   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; OSELTAMIVIR; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC DISEASE; CHRONIC PATIENT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; FLU LIKE SYNDROME; HEALTH CARE COST; HUMAN; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; PANDEMIC; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SENSITIVITY ANALYSIS; THEORETICAL MODEL; VIRUS PNEUMONIA;

AGED; ANTIVIRAL AGENTS; CHRONIC DISEASE; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INFLUENZA, HUMAN; MALE; MODELS, ECONOMIC; NETHERLANDS; OSELTAMIVIR; RISK;

EID: 34249785109     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725060-00005     Document Type: Article

References (53)

1. Postma MJ, Baltussen R, Heijnen M-LA, et al. Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence. Drugs Aging 2000; 17 Suppl. 3: 217-27
2. Postma MJ, Baltussen R, Wilschut JC. A synthesis of further evidence for favourable cost-effectiveness of elderly influenza vaccination. Expert Rev Pharmacoeconomics Outcomes Res 2006; 6: 215-27
3. Nichol KL, Goodman M. The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years. Pharmacoeconomics 1999; 16 Suppl. 1: 63-71
4. Wood SC, Nguyen VH, Schmidt C. Economic evaluations of influenza vaccination in the elderly: impact on public health policy. Dis Manage Health Outcomes 2000; 8: 273-85
5. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163: 1667-72
6. Stichting Farmaceutische Kengetallen [online]. Available from URL: http://www.sfk.nl [Accessed 2005 Nov 12]
7. National Institute for Clinical Excellence (NICE). Guidance on the use of zanamivir, oseltamivir and amantadine for treatment of influenza: technology appraisal guidance no. 58. London: NICE, 2003
8. MIST Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352: 1877-81
9. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254-61
10. Nicholson KG, Aoki FY, Osterhaus ADME, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 2000; 355: 1845-50
11. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336-43
12. Treanor JT, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza; a randomized controlled trial. JAMA 2000; 283: 1016-24
13. Rutten F. Health technology assessment and policy from the economic perspective. Int J Technol Assessment Health Care 2004; 20: 67-70
14. Postma MJ, Bos JM, van Gennep M, et al. Economic evaluation of influenza vaccination: assessment for The Netherlands. Pharmacoeconomics 1999; 16 Suppl. 1: 33-40
15. Van Genugten MLL, Heijnen M-LA, Jager JC. Pandemic influenza and healthcare demand in The Netherlands: scenario analysis. Emerg Infect Dis 2003; 9: 531-8
16. National Institute of Public Health and the Environment. Meeting of Dutch experts on influenza. 2001 Jul 2; Bilthoven
17. Hennekens CH, Buring JE. Epidemiology in medicine. Philadelphia (PA): Lippincott, Williams & Wilkins, 1987
18. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation. Med Decis Making 1985; 5: 157-77
19. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine: part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol 2004; 19: 365-75
20. Baltussen RMPM, Reinders A, Sprenger MJW, et al. Estimating influenza-related hospitalisation in The Netherlands. Epidemiol Infect 1998; 121: 129-38
21. Sprenger MJW, Mulder PGH, Beyer WEP, et al. Impact of influenza on mortality in relation to age and underlying diseases, 1967-1989. Int J Epidemiol 1993; 22: 333-9
22. Cox NJ, Subbarao K. Influenza. Lancet 1999; 354: 1277-82
23. Couch RB. Prevention and treatment of influenza. NEJM 2000; 343: 1778-87
24. Central Bureau of Statistics of The Netherlands [online]. Available at URL: http://www.cbs.nl [Accessed 2005 Nov 12]
25. Centraal Bureau voor de Statistiek [online]. Available from URL: http://statline.cbs.nl/StatWeb [Accessed 2005 Nov 12]
26. College voor Zorgverzekeringen (CvZ). Guidelines for pharmaco-economic research. Amstelveen: CvZ, 1999
27. Klok RM, Brouwer WBF, Annemans LJP, et al. Towards a healthier discount procedure. Expert Rev Pharmacoeconomics Outcomes Res 2005; 5: 59-63
28. Prismant for Health Care, Utrecht [online]. Available at URL: http://www.prismant.nl [Accessed 2005 Nov 12]
29. Postma MJ, Heijnen M-LA, Jager JC. Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands. Pharmacoeconomics 2001; 19 (2): 215-22
30. Postma MJ, Jansema P, Scheijbeler HWKFH, et al. Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults. Vaccine 2005; 23: 5365-71
31. Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001; 161: 749-59
32. Demichelli V, Jefferson T, Rivetti D, et al. Prevention and early treatment of influenza in healthy adults. Vaccine 2000; 18: 957-1030
33. Akazawa M, Sindelar JL, Paltiel D. Economic costs of influenza-related work absenteeism. Value Health 2003; 6: 107-15
34. Campbell DS, Rumley MH. Cost-effectiveness of the influenza vaccine in a healthy working-age population. J Occup Environ Med 1997; 39: 408-14
35. Szucs T. The socio-economic burden of influenza. J Antimicrob Chemother 1999; 44: 11-5
36. Keech M, Scott AJ, Ryan PJJ. The impact of influenza and influenza-like-illness on productivity and healthcare resource utilisation in a working population. Occup Med 1998; 48: 85-90
37. College voor Zorgverzekeraars (CvZ). Guideline prices for pharmaco-economic research. Diemen: CvZ, 2004
38. College voor Zorgverzekeringen (CvZ). Farmacotherapeutisch kompas 2002. Amstelveen: CvZ, 2002
39. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza. JAMA 1999; 282: 1240-6
40. Brouwer WBF, Niessen LW, Postma MJ, et al. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 2005; 331: 446-8
41. Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health 2005; 8: 1-2
42. Postma MJ. Re: Tamiflu: NNT to prevent a pandemic flu death may be a million. BMJ 2005 Dec 7 [online]. Available from URL: http://www.bmj.com/cgi/ eletters/331/7526/1203-b#123247 [Accessed 2007 Apr 27]
43. Voordouw BC, van der Linden PD, Simonian S, et al. Influenza vaccination in community-dwelling elderly: impact on mortality and influenza-associated morbidity. Arch Intern Med 2003; 163: 1089-94
44. Hak E, Buskens E, van Essen GA, et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. Arch Intern Med 2005; 165: 274-80
45. Longini IM Jr, Halloran ME, Nizam A, et al. Containing pandemic influenza with antiviral agents. Am J Epidemiol 2004; 159: 623-33
46. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20: 127-33
47. Reisinger K, Greene G, Aultman R, et al. Effect of influenza treatment with oseltamivir on health outcome and costs in otherwise healthy children. Clin Drug Invest 2004; 24: 395-407
48. Husereau DR, Brady B, McGeer A. An assessment of oseltamivir for the treatment of suspected influenza. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment, 2001
49. Inoue T, Watanabe K, Chonabayashi N, et al. Pharmacoeconomics of antiviral therapy for influenza in a Japanese hospital setting. Clin Drug Invest 2005; 25: 49-63
50. Sander B, Gyldmark M, Aultman R, et al. Impact on health outcome and costs of influenza treatment with oseltamivir in elderly and high-risk patients. J Med Econ 2004; 7: 67-83
51. Rothberg MB, Bellantonio S, Rose DN. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. Ann Intern Med 2003; 139: 321-9
52. Bos JM, Postma MJ. Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness? Expert Rev Pharmacoeconomics Outcomes Res 2004; 4: 247-50
53. Tolley K, Postma MJ. Pharmacoeconomics and market access in Europe: case studies in Scotland and The Netherlands. ISPOR Connections 2006 Oct 15; 12: 3-6